keyword
https://read.qxmd.com/read/38645403/beyond-distribution-shift-spurious-features-through-the-lens-of-training-dynamics
#21
JOURNAL ARTICLE
Nihal Murali, Aahlad Puli, Ke Yu, Rajesh Ranganath, Kayhan Batmanghelich
Deep Neural Networks (DNNs) are prone to learning spurious features that correlate with the label during training but are irrelevant to the learning problem. This hurts model generalization and poses problems when deploying them in safety-critical applications. This paper aims to better understand the effects of spurious features through the lens of the learning dynamics of the internal neurons during the training process. We make the following observations: (1) While previous works highlight the harmful effects of spurious features on the generalization ability of DNNs, we emphasize that not all spurious features are harmful...
October 2023: Transact Mach Learn Res
https://read.qxmd.com/read/38644625/effect-of-daridorexant-on-sleep-architecture-in-patients-with-chronic-insomnia-disorder-a-pooled-post-hoc-analysis-of-two-randomized-phase-3-clinical-studies
#22
JOURNAL ARTICLE
Tobias Di Marco, Ina Djonlagic, Yves Dauvilliers, Kolia Sadeghi, David Little, Alexandre N Datta, Jeffrey Hubbard, Göran Hajak, Andrew Krystal, Antonio Olivieri, Liborio Parrino, Corey B Puryear, Gary Zammit, Jacob Donoghue, Thomas E Scammell
STUDY OBJECTIVES: Post-hoc analysis to evaluate the effect of daridorexant on sleep architecture in people with insomnia, focusing on features associated with hyperarousal. METHODS: We studied sleep architecture in adults with chronic insomnia disorder from two randomized Phase 3 clinical studies (Clinicaltrials.gov: NCT03545191 and NCT03575104) investigating 3 months of daridorexant treatment (placebo, daridorexant 25 mg, daridorexant 50 mg). We analyzed sleep-wake transition probabilities, EEG spectra and sleep spindle properties including density, dispersion, and slow oscillation phase coupling...
April 22, 2024: Sleep
https://read.qxmd.com/read/38644146/deep-and-durable-prostate-specific-antigen-response-to-darolutamide-with-androgen-deprivation-therapy-and-docetaxel-and-association-with-clinical-outcomes-for-patients-with-high-or-low-volume-metastatic-hormone-sensitive-prostate-cancer-analyses-of-the-randomized
#23
JOURNAL ARTICLE
Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Cora N Sternberg, E David Crawford, Luke T Nordquist, Martin Bögemann, Ronald Tutrone, Neal D Shore, Laurence Belkoff, Todd Fralich, Jay Jhaveri, Shankar Srinivasan, Rui Li, Frank Verholen, Iris Kuss, Matthew R Smith
BACKGROUND AND OBJECTIVE: Addition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. METHODS: ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel...
April 20, 2024: European Urology
https://read.qxmd.com/read/38644027/influence-of-biomass-burning-on-ozone-levels-in-the-megalopolis-of-central-mexico-during-the-covid-19-lockdown
#24
JOURNAL ARTICLE
Victor Almanza, Luis Gerardo Ruiz-Suárez, Ricardo Torres-Jardón, Agustín García-Reynoso, Iván Y Hernández-Paniagua
The massive reductions in anthropogenic emissions resulting from the COVID-19 lockdown provided a unique opportunity to evaluate the effect of mitigation measures aiming to abate air pollution. In Mexico, the total lockdown period took place during the dry-hot season when biomass burning activity is enhanced. Here, we investigate the role of biomass burning emissions on regional ozone levels in the Megalopolis of Central Mexico. The studied period covers the lockdown phases 2 and 3, and the first month of the New Normal...
September 2024: Journal of Environmental Sciences (China)
https://read.qxmd.com/read/38643780/early-postnatal-high-dose-fat-soluble-enteral-vitamin-a-supplementation-for-moderate-or-severe-bronchopulmonary-dysplasia-or-death-in-extremely-low-birthweight-infants-neovitaa-a-multicentre-randomised-parallel-group-double-blind-placebo-controlled-investigator
#25
JOURNAL ARTICLE
Sascha Meyer, Johannes Bay, Axel R Franz, Harald Erhardt, Lars Klein, Jutta Petzinger, Christoph Binder, Susanne Kirschenhofer, Anja Stein, Britta Hüning, Axel Heep, Eva Cloppenburg, Julia Muyimbwa, Torsten Ott, Julia Sandkötter, Norbert Teig, Susanne Wiegand, Michael Schroth, Andrea Kick, Donald Wurm, Corinna Gebauer, Knud Linnemann, Jochen Kittel, Christian Wieg, Ursula Kiechl-Kohlendorfer, Susanne Schmidt, Ralf Böttger, Wolfgang Thomas, Francisco Brevis Nunez, Antje Stockmann, Thomas Kriebel, Andreas Müller, Daniel Klotz, Patrick Morhart, Donatus Nohr, Hans Konrad Biesalski, Eleni Z Giannopoulou, Susanne Hilt, Martin Poryo, Stefan Wagenpfeil, Nadja Haiden, Christian Ruckes, Anne Ehrlich, Ludwig Gortner
BACKGROUND: Vitamin A plays a key role in lung development, but there is no consensus regarding the optimal vitamin A dose and administration route in extremely low birthweight (ELBW) infants. We aimed to assess whether early postnatal additional high-dose fat-soluble enteral vitamin A supplementation versus placebo would lower the rate of moderate or severe bronchopulmonary dysplasia or death in ELBW infants receiving recommended basic enteral vitamin A supplementation. METHODS: This prospective, multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial conducted at 29 neonatal intensive care units in Austria and Germany assessed early high-dose enteral vitamin A supplementation (5000 international units [IU]/kg per day) or placebo (peanut oil) for 28 days in ELBW infants...
April 18, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38643547/estimating-vaccine-efficacy-during-open-label-follow-up-of-covid-19-vaccine-trials-based-on-population-level-surveillance-data
#26
JOURNAL ARTICLE
Mia Moore, Yifan Zhu, Ian Hirsch, Tom White, Robert C Reiner, Ryan M Barber, David Pigott, James K Collins, Serena Santoni, Magdalena E Sobieszczyk, Holly Janes
While rapid development and roll out of COVID-19 vaccines is necessary in a pandemic, the process limits the ability of clinical trials to assess longer-term vaccine efficacy. We leveraged COVID-19 surveillance data in the U.S. to evaluate vaccine efficacy in U.S. Government-funded COVID-19 vaccine efficacy trials with a three-step estimation process. First, we used a compartmental epidemiological model informed by county-level surveillance data, a "population model", to estimate SARS-CoV-2 incidence among the unvaccinated...
April 15, 2024: Epidemics
https://read.qxmd.com/read/38643510/phase-3-randomized-trial-of-mavorixafor-cxcr4-antagonist-in-whim-syndrome
#27
JOURNAL ARTICLE
Raffaele Badolato, Laia Alsina, Antoine Azar, Yves Bertrand, Audrey A Bolyard, David C Dale, Àngela Deyà-Martinez, Kathryn E Dickerson, Navid Ezra, Henrik Hasle, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W Kuijpers, Alexander Kulagin, Daman Langguth, Carina Levin, Olaf Neth, Peter Olbrich, Jane Peake, Yulia Rodina, Caroline E Rutten, Anna Shcherbina, Teresa K Tarrant, Matthias G Vossen, Christian A Wysocki, Andrea Belschner, Gary J Bridger, Kelly Chen, Susan Dubuc, Yanping Hu, Honghua Jiang, Sunny Li, Rick MacLeod, Murray Stewart, Arthur G Taveras, Tina Yan, Jean Donadieu
We investigated efficacy and safety of mavorixafor, an oral CXCR4 antagonist for participants with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, a rare immunodeficiency caused by CXCR4 gain-of-function variants. This randomized (1:1), double-blind, placebo-controlled, phase 3 trial enrolled participants aged ≥12 years with WHIM syndrome and absolute neutrophil count (ANC) ≤400/μL. Participants received once-daily mavorixafor or placebo for 52 weeks. Primary endpoint was time (hours) above ANC threshold ≥500/μL (TATANC; over 24 hours)...
April 21, 2024: Blood
https://read.qxmd.com/read/38643311/pharmacokinetic-study-of-capivasertib-and-the-cyp3a4-substrate-midazolam-in-patients-with-advanced-solid-tumors
#28
JOURNAL ARTICLE
Claire Miller, Roberto Sommavilla, Cindy L O'Bryant, Minal Barve, Afshin Dowlati, Jason J Luke, Mahmuda Khatun, Thomas Morris, Marie Cullberg
PURPOSE: Capivasertib, a potent, selective inhibitor of all three AKT serine/threonine kinase (AKT) isoforms, is being evaluated in phase 3 trials in advanced breast and prostate cancer. This study evaluated the drug-drug interaction risk of capivasertib with the cytochrome P450 3A substrate midazolam in previously treated adults with advanced solid tumors. METHODS: Patients received oral capivasertib 400 mg twice daily (BID) on an intermittent schedule (4 days on/3 days off) starting on day 2 of cycle 1 (29 days) and on day 1 of each 28-day cycle thereafter...
April 20, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38642841/pembrolizumab-plus-chemotherapy-for-metastatic-non-small-cell-lung-cancer-with-programmed-cell-death-ligand-1-tumor-proportion-score-less-than-1-pooled-analysis-of-outcomes-after-5-years-of-follow-up
#29
JOURNAL ARTICLE
Shirish M Gadgeel, Delvys Rodríguez-Abreu, Balazs Halmos, Marina C Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz-Ares
BACKGROUND: We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy. METHODS: This exploratory pooled analysis included individual patient data from the KEYNOTE-189 global (NCT02578680) and Japan extension (NCT03950674) studies of metastatic nonsquamous NSCLC without EGFR or ALK alterations and the KEYNOTE-407 global (NCT02775435) and China extension (NCT03875092) studies of metastatic squamous NSCLC...
April 18, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38642278/emotional-and-functional-well-being-in-long-term-breast-cancer-survivorship
#30
JOURNAL ARTICLE
Yumeng Ren, Joanna Maselko, Xianming Tan, Andrew F Olshan, Angela M Stover, Antonia V Bennett, Katherine E Reeder-Hayes, Jessie K Edwards, Bryce B Reeve, Melissa A Troester, Marc A Emerson
PURPOSE: Emotional and functional well-being (EWB and FWB) are important components of mental health and quality of life. This study aims to evaluate long-term EWB and FWB in breast cancer (BC) survivors. METHODS: The Carolina Breast Cancer Study Phase 3 oversampled Black and younger (< 50 years in age) women so that they each represent approximately 50% of the study population and assessed participants' EWB and FWB with the Functional Assessment of Cancer Therapy-Breast (FACT-B) at 5- (baseline), 25-, and 84-months post diagnosis...
April 20, 2024: Cancer Causes & Control: CCC
https://read.qxmd.com/read/38641335/pharmacokinetics-of-edoxaban-15%C3%A2-mg-in-very-elderly-patients-with-nonvalvular-atrial-fibrillation-a-subanalysis-of-the-eldercare-af-study
#31
JOURNAL ARTICLE
Takeshi Yamashita, Yoshiyuki Igawa, Masayuki Fukuzawa, Takuya Hayashi, Stefanie Hennig, Ken Okumura
BACKGROUND:  We evaluated the pharmacokinetics (PK) of low-dose (15 mg) edoxaban in very elderly patients (≥80 years) with nonvalvular atrial fibrillation (NVAF) and high bleeding risk. METHODS:  This subanalysis of the phase 3, randomized, double-blind, placebo-controlled, multicenter ELDERCARE-AF study evaluated edoxaban plasma concentrations and compared them with the Japanese population of the ENGAGE AF-TIMI 48 and Japanese severe renal impairment (SRI) studies...
April 19, 2024: Thrombosis and Haemostasis
https://read.qxmd.com/read/38640629/monitoring-vegetable-dehydration-process-by-aquaphotomics-from-lab-scale-to-farm
#32
JOURNAL ARTICLE
Tiziana M P Cattaneo, Laura Marinoni
Solar dehydration processes, implemented with NIR sensors, were studied. The research plan was divided into phases to achieve specific objectives. Phase 1: laboratory tests on micro plants; phase 2: scale transposition tests on small-sized plants - pilot scale; phase 3: tests on commercial systems already in use by Italian SMEs. The realisation of the scheduled activities started with the design, programming, and positioning of NIR sensor for data collection and configuration optimization. NIR spectra were collected in reflectance mode (900-1700 nm) using the MicroNIR1700™ or the MicroNIR On-site W™ (VIAVI Solutions Italia S...
April 16, 2024: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://read.qxmd.com/read/38638168/recent-advances-in-systemic-therapy-for-advanced-intrahepatic-cholangiocarcinoma
#33
REVIEW
Changhoon Yoo, Jaewon Hyung, Stephen L Chan
BACKGROUND: The incidence of intrahepatic cholangiocarcinoma (IHCCA) is rising around the world. The disease is becoming a major global health issue. Conventionally, most patients with cholangiocarcinoma present with advanced disease and systemic therapy is the mainstay of treatment. This review discusses recent advances in systemic treatments for patients with IHCCA. SUMMARY: The addition of durvalumab to a gemcitabine plus cisplatin regimen has significantly improved overall survival in the phase 3 TOPAZ-1 trial and is currently recommended as a standard first-line treatment...
April 2024: Liver Cancer
https://read.qxmd.com/read/38637636/an-omicron-specific-self-amplifying-mrna-booster-vaccine-for-covid-19-a-phase-2-3-randomized-trial
#34
JOURNAL ARTICLE
Amit Saraf, Rohan Gurjar, Swarnendu Kaviraj, Aishwarya Kulkarni, Durgesh Kumar, Ruta Kulkarni, Rashmi Virkar, Jayashri Krishnan, Anjali Yadav, Ekta Baranwal, Ajay Singh, Arjun Raghuwanshi, Praveen Agarwal, Laxman Savergave, Sanjay Singh
Here we conducted a multicenter open-label, randomized phase 2 and 3 study to assess the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-specific (BA.1/B.1.1.529), monovalent, thermostable, self-amplifying mRNA vaccine, GEMCOVAC-OM, when administered intradermally as a booster in healthy adults who had received two doses of BBV152 or ChAdOx1 nCoV-19. GEMCOVAC-OM was well tolerated with no related serious adverse events in both phase 2 and phase 3. In phase 2, the safety and immunogenicity of GEMCOVAC-OM was compared with our prototype mRNA vaccine GEMCOVAC-19 (D614G variant-specific) in 140 participants...
April 18, 2024: Nature Medicine
https://read.qxmd.com/read/38637211/immunogenicity-and-safety-of-a-14-valent-pneumococcal-polysaccharide-conjugate-vaccine-pneubevax-14%C3%A2-administered-to-6-8%C3%A2-weeks-old-healthy-indian-infants-a-single-blind-randomized-active-controlled-phase-iii-study
#35
JOURNAL ARTICLE
Ramesh V Matur, Subhash Thuluva, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Kamal Thammireddy, Piyush Paliwal, Niranjana S Mahantshetty, Mandyam Dhati Ravi, S Prashanth, Savita Verma, Jai Prakash Narayan
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing pneumococcal vaccines, particularly impacting pediatric and elder population. In addition, the regions where the PCV is not available, the disease burden remains high. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14™; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) was evaluated in infants in comparison to licensed vaccine, Prevenar-13 (PCV-13)...
April 17, 2024: Vaccine
https://read.qxmd.com/read/38636709/using-the-genomic-adjusted-radiation-dose-gard-to-personalize-the-radiation-dose-in-nasopharyngeal-cancer
#36
JOURNAL ARTICLE
Chi Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li, Wai Tong Ng, James Chung Hang Chow, Horace Cheuk Wai Choi, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Steven A Eschrich, Javier F Torres-Roca, Jason Wing Hon Wong
BACKGROUND: Locally advanced nasopharyngeal cancer (NPC) patients undergoing radiotherapy are at risk of treatment failure, particularly locoregional recurrence. To optimize the individual radiation dose, we hypothesize that the genomic adjusted radiation dose (GARD) can be used to correlate with locoregional control. METHODS: A total of 92 patients with American Joint Committee on Cancer / International Union Against Cancer stage III to stage IVB recruited in a randomized phase III trial were assessed (NPC-0501) (NCT00379262)...
April 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38636702/reserpine-induced-rat-model-for-depression-behavioral-physiological-and-pet-based-dopamine-receptor-availability-validation
#37
JOURNAL ARTICLE
Lidia Miguel Telega, Raissa Berti, Ganna Blazhenets, Lisa-Charlotte Domogalla, Nils Steinacker, M Aymen Omrane, Philipp T Meyer, Volker A Coenen, Ann-Christin Eder, Máté D Döbrössy
BACKGROUND: Reserpine (RES), a Vesicular Monoamine Transporter 2 (VMAT2 ) inhibitor agent, has been used in preclinical research for many years to create animal models for depression and to test experimental antidepressant strategies. Nevertheless, evidence of the potential use and validity of RES as a chronic pharmacological model for depression is lacking, and there are no comprehensive studies of the behavioral effects in conjunction with molecular outcomes. METHODS: Experiment 1...
April 16, 2024: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://read.qxmd.com/read/38635724/evaluating-the-efficacy-and-safety-of-mavacamten-in-hypertrophic-cardiomyopathy-a-systematic-review-and-meta-analysis-focusing-on-qualitative-assessment-biomarkers-and-cardiac-imaging
#38
JOURNAL ARTICLE
Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi
BACKGROUND: Hypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT). Mavacamten, a first-in-class cardiac myosin inhibitor, is increasingly being studied in randomized controlled trials. In this meta-analysis, we aimed to analyse the efficacy and safety profile of Mavacamten compared to placebo in patients of HCM. METHOD: We carried out a comprehensive search in PubMed, Cochrane, and clinicaltrials...
2024: PloS One
https://read.qxmd.com/read/38635695/health-care-utilisation-of-asylum-seekers-and-refugees-in-the-south-west-of-germany
#39
JOURNAL ARTICLE
Annabelle J Bockey, Cornelia Braun, Johannes Camp, Aleš Janda, Winfried V Kern, Anne-Maria Müller, Katarina Stete, Siegbert R Rieg, Berit Lange
BACKGROUND: Limited evidence on utilisation of health care by recently arrived asylum seekers and refugees in high-income countries is available. This study aims to describe the implementation of an integrated care facility (ICF) in an initial reception centre and measure the utilisation of care and the influence of operational parameters. METHODS: In a retrospective cohort study design, using medical records, we followed inhabitants of a reception centre in Germany between 11...
2024: PloS One
https://read.qxmd.com/read/38635499/impact-of-apoe-%C3%AE%C2%B5-alleles-on-brain-structure-and-cognitive-function-in-healthy-older-adults-a-vbm-and-dti-replication-study
#40
JOURNAL ARTICLE
Colleen Lacey, Theone Paterson, Jodie R Gawryluk
BACKGROUND: The Apolipoprotein E (APOE) gene has been established in the Alzheimer's disease (AD) literature to impact brain structure and function and may also show congruent effects in healthy older adults, although findings in this population are much less consistent. The current study aimed to replicate and expand the multimodal approach employed by Honea et al. Structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), and neuropsychological measures were used to investigate the impact of APOE-ε status on grey matter structure, white matter integrity, and cognitive functioning...
2024: PloS One
keyword
keyword
91259
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.